Easton Pharmaceuticals Announces it has Reached a Manufacturing Agreement for the Companys OTC Products; Advances Timetable for Product Launch - WALB.com, Albany News, Weather, Sports

Easton Pharmaceuticals Announces it has Reached a Manufacturing Agreement for the Companys OTC Products; Advances Timetable for Product Launch

Posted: Updated:

TORONTO, ON / ACCESSWIRE / August 14, 2014 / Easton Pharmaceuticals (OTC Pink: EAPH) (PINKSHEETS: EAPH)  announces they have sourced out, come to terms and agreed to enter into an agreement with a manufacturing partner for the North American Market and is finalizing a manufacturing Agreement for the Latin American market. Company advances timetable towards its OTC product launches.

 

Easton Pharmaceuticals has agreed and come to terms with a GMP certified manufacturer located in Toronto, Canada, who will manufacture and supply the U.S. and Canadian markets. Pricing has been determined to be on par with Mexican manufacturers, but the company believes quality control can be better managed in local jurisdictions. Final agreements with the manufacturing company are being drafted who have manufactured and packaged dozens of products for various company’s across North America. In addition, Easton has entered into negotiations with other companies for distribution of its OTC products and is close to finalizing an agreement to allow for the marketing and sale of the company’s products to commence sometime in the very near term. A formal announcement on the North American manufacturing partner and what we believe to be significant developments involving a distribution partner on our OTC products and other well sought after products within the medical marijuana industry, is anticipated sometime within the next 2 to 3 weeks.

 

It is expected that the Latin and South American efforts, namely the country of Mexico will still have its manufacturing realized in Mexico. BMV Medica, and Dr. Daniel Bagi, a consultant for Easton Pharmaceuticals have reached an agreement in principle with a manufacturer in Mexico. Initial discussions with another FDA approved manufacturer in Mexico were canceled due to pricing dis-agreements with the company. As previously announced, Easton will be using BMV Medica for its distribution of various products in Mexico and Latin American markets

 

Carla Pepe, CEO of Easton Pharmaceuticals, commented “Although the launch of Viorra and our other OTC products have recently taken a bit of a back seat to our medical marijuana initiatives, much of the ground work has been laid out where the company now feels it should now move towards manufacturing, marketing and distribution in a diligent and expeditious manner.  We anticipate positive announcements will soon be forthcoming that will demonstrate our commitment to our OTC products in conjunction with our medical marijuana initiatives.

 

About Easton Pharmaceuticals

Easton Pharmaceuticals is a specialty pharmaceutical company involved in various pharmaceutical sectors and others industries such as medical marijuana. The Company owns, designs, develops, and markets topically-delivered drugs and therapeutic / cosmetic healthcare products, focused on cancer and other health issues geared towards male and female sexual dysfunction, wound healing, pain, motion sickness, scar and stretch marks, cellulite, varicose veins and other conditions. The company has ventured into the potentially lucrative medical marijuana industry through an investment into AMFIL Technologies and their groZONE anti-bacterial system and the exclusive option to purchase up to 50% in a medical marijuana grow-op business / facility which has received a letter to build from Health Canada. The company’s gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of Cannabidiol extracts.

 

For More Information Visit:

http://www.eastonpharmaceuticalsinc.com

 

Safe Harbor

This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (The “Act”). In particular, when used in the preceding of discussion, the words “anticipate,” “pleased,” “plan,” “confident that,” “believe,” “expect,” “possible” or “intent to” and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals would be classified as speculative. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company’s products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company’s financial reports and filings.

 

Contact:

 

Carla Pepe

Easton Pharmaceuticals Inc.

Tel: +1(416) 619-0291

Tel: +1(347) 284-0192

Email: info@eastonpharmaceuticalsinc.com

 

SOURCE: Easton Pharmaceuticals, Inc.

ReleaseID: 419145